Fingerprint
Dive into the research topics of 'Pembrolizumab for Previously Treated, PD-L1–expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Pembrolizumab for Previously Treated, PD-L1–expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, Bilal Piperdi, Thomas Burke
Research output: Contribution to journal › Article › peer-review
7
Scopus
citations